Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans

Circulation Journal

Volumn 76, Issue 8, 2012, Pages 2023-2030

  Nochioka, Kotaro ^a   Tanaka, Shin ichi ^a   Miura, Masanobu ^a   Zhulanqiqige, Do e ^a   Fukumoto, Yoshihiro ^a   Shiba, Nobuyuki ^a,b   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Ezetimibe; Flow mediated dilatation; LDL cholesterol; Rho kinase

Indexed keywords

C REACTIVE PROTEIN; CAMPESTEROL; CHOLESTANOL; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RHO KINASE; TRIACYLGLYCEROL;

ADULT; ARTERY DILATATION; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; LEUKOCYTE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTANOL; CHOLESTEROL; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTESTINAL ABSORPTION; LEUKOCYTES; MALE; PRAVASTATIN; RHO-ASSOCIATED KINASES; UP-REGULATION;

EID: 84864381351     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0331     Document Type: Article

References (31)

1. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-1204.
2. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-955.
3. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443.
4. Baigent C, Landray MJ, Emberson J, Wheeler DC, Tomson C, Wanner C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): A randomized placebo-controlled trial. Lancet 2011; 377: 2181-2192.
5. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesion of atherosclerosis. Science 1973; 180: 1332-1339.
6. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
7. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007; 28: 296-302.
8. Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnantlike particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 2010; 17: 37-44.
9. Oi K, Shimokawa H, Hiroki J, Uwatoku T, Abe K, Matsumoto Y, et al. Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rhokinase. Artherioscler Thromb Vasc Biol 2004; 25: 918-922.
10. Staprans L, Pan XM, Rapp JH, Moser AH, Feingold KR. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res 2006; 47: 2575-2580.
11. Clarenbach JJ, Reber M, Lütjohann D, von Bergmann K, Sudhop T. The lipid-lowering effect of ezetimibe in pure vegetarians. J Lipid Res 2006; 47: 2820-2824.
12. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009; 73: 361-370.
13. Haffner SM, Miettinen H, Stern MP. The homeostasis model the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.
14. Do.e Z, Fukumoto Y, Takaki A, Tawara S, Ohasi J, Nakano M, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009; 73: 1731-1739.
15. Watanabe K, Oba K, Suzuki T, Ouchi M, Suzuki K, Futami-Suda S, et al. Oral glucose loading attenuates endothelial function in normal individual. Eur J Clin Invest 2011; 41: 465-473.
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajier D, Charbonnearu F, Creager MA, et al; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002; 39: 257-265.
17. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769-1775.
18. Tomiyama H, Yamashina A. Non-invasive function tests: Their pathophysiological background and clinical application. Circ J 2010; 74: 24-33.
19. Salen G, Grundy SM. The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis. J Clin Invest 1973; 52: 2822-2835.
20. Bhattacharyya AK, Connor WE. Familial diseases with storage of sterols other than cholesterol. Cerebrotendinous xanthomatosis, and beta-sitosterolemia and xanthomatosisi. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1978; 656-669.
21. Miettinen TA, Tilvis RS, Kesäniemi YA. Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men. Metabolism 1989; 38: 136-140.
22. Miettinnen TA, Gylling H, Standberg T, Sarna S. Baseline serum chorestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. BMJ 1998; 316: 1127-1130.
23. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-2363.
24. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008; 118: 1632-1644.
25. Matthan NR, Pencina M, LaRocque JM, Jacques PF, D'Aqostino RB, Schaefer EJ, et al. Alternations in cholesterol absorption/synthesis makers characterize Framingham offspring study participants with CHD. J Lipid Res 2009; 50: 1927-1935.
26. Sano K, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, et al. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 2010; 74: 1644-1650.
27. Glueck CJ, Speris J, Tracy T, Streicher P, IIIiq E, Vandegriff J. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism 1991; 40: 842-848.
28. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effects on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767-775.
29. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004; 37: 537-546.
30. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotrophy in humans: Differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009; 119: 131-138.
31. Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, et al. The Anglo-Scandinavian cardiac outcomes trial lipid lowering arm: Extended observations2 years after trial closure. Eur Heart J 2008; 29: 499-508.